# Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)

> **NCT01879007** · PHASE1 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 16 (actual)

## Conditions studied

- Infectious Diseases

## Interventions

- **DRUG:** Factive® Tab / Factive IV

## Key facts

- **NCT ID:** NCT01879007
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01879007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01879007, "Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01879007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*